Hariharan Nisha, Kabadi Alisha, Don Michelle, Odish Mazen, Heyman Benjamin
Department of Medicine, Division of Hematology/Oncology, University of California, La Jolla, CA 92093, USA.
Department of Medicine, Division of Pulmonary, Critical Care, Sleep Medicine, and Physiology, University of California, La Jolla, CA 92093, USA.
Hematol Rep. 2023 Nov 16;15(4):627-633. doi: 10.3390/hematolrep15040064.
Diffuse large B-cell lymphoma (DLBCL) and angioimmunoblastic T-cell lymphoma (AITL) are two subtypes of non-Hodgkin lymphoma (NHL). The simultaneous occurrence of DLBCL and AITL in a composite lymphoma is very rare, and there are no established treatment regimens. We present the case of an 85-year-old male admitted to the intensive care unit with distributive shock, lymphocytosis, and lymphadenopathy, who was subsequently diagnosed with composite AITL and DLBCL, and treated with brentuximab vedotin (BV) and rituximab. To our knowledge, this is the first case of composite lymphoma presenting with distributive shock and treated with BV and rituximab, with successful resolution of shock.
弥漫性大B细胞淋巴瘤（DLBCL）和血管免疫母细胞性T细胞淋巴瘤（AITL）是非霍奇金淋巴瘤（NHL）的两种亚型。复合淋巴瘤中同时出现DLBCL和AITL非常罕见，且尚无既定的治疗方案。我们报告了一例85岁男性患者，因分布性休克、淋巴细胞增多和淋巴结病入住重症监护病房，随后被诊断为复合性AITL和DLBCL，并接受了维布妥昔单抗（BV）和利妥昔单抗治疗。据我们所知，这是首例以分布性休克为表现并接受BV和利妥昔单抗治疗的复合淋巴瘤病例，休克成功得到缓解。
